Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

SUNPHARMA's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.046993
debtToEquity 3.259000
earningsGrowth -0.195000
revenueGrowth 0.095000
grossMargins 0.782480
operatingMargins 0.243450
trailingEps 43.250000
forwardEps 32.680000

SUNPHARMA's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
With both earnings and revenue growth in low territory, SUNPHARMA is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
Positive gross and operating margins for SUNPHARMA demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
SUNPHARMA's lower forward EPS compared to trailing EPS suggests the company's earnings are expected to decline. This indicates that SUNPHARMA may be less profitable in the upcoming year, raising questions about its financial trajectory.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

SUNPHARMA's price projections have been revised downward over time, reflecting a shift in sentiment among analysts. The steady decline in projections points to a more cautious outlook on the company's future performance.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


The analysts' recent buy bias for SUNPHARMA indicates strong confidence in the stock's future performance. This could encourage more investors to view SUNPHARMA as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.